Careers  |  Sign In  |  Register  |   Twitter

Riociguat Demonstrates Efficacy for Pulmonary Hypertension

An article in Forbes reports that Riociguat, a drug under development from Bayer, shows “promising” effects for people suffering from two types of pulmonary hypertension. Two new studies examined the effects of treatment for two groups, one with 262 patients suffering from chronic thromboembolic pulmonary hypertension (CTEPH) and another with 443 pulmonary arterial hypertension (PAH) patients, compared to placebo groups. The CTEPH group showed a 39-meter increase in 6-minute walking distance after 16 weeks of treatment and the PAH group showed a 30-meter increase. Researchers concluded that Riociguat may offer an alternative to pulmonary endarterectomy surgery, which is a “difficult procedure that should only be performed at a very few centers.”

Read it in Forbes.

Read the pulmonary arterial hypertension study in NEJM.

Read the chronic thromboembolic pulmonary hypertension study in NEJM.